Jinwon Life Sciences Signs $2 Million Plasmid DNA Drug Supply Contract
[Asia Economy Reporter Jang Hyowon] Jinwon Life Sciences announced on the 8th that it has signed a plasmid DNA pharmaceutical supply contract worth 2 million dollars with a US biotech company.
Jinwon Life Sciences supplies high-quality plasmid DNA pharmaceuticals through its subsidiary VGXI, a US-based cGMP (current Good Manufacturing Practice) contract development and manufacturing organization (CDMO). Currently, a large-scale new facility is being constructed on the production site located in Conroe, Texas, equipped with a quality evaluation laboratory, purification and filling, packaging facilities, raw material warehouses, spaces necessary for process support, as well as offices and convenience facilities.
Hot Picks Today
"How Much Will They Get?" 600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division's 'Three Wallets Under One Roof'
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Samsung Electronics Labor-Management Agreement, Nvidia Revenue Surges... KOSPI Soars Over 6%
- "Disappointing Results: 80% of Sunscreens Found Lacking in Safety and Effectiveness"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Park Younggeun, CEO of Jinwon Life Sciences, stated, “VGXI is a global leader in contract manufacturing supplying high-quality plasmids, and we expect steady large-scale supply contracts to be signed this year as well.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
